|
Initial therapy for chronic myelogenous leukemia: playing the odds |
| |
SJ Lee, C Anasetti, MM Horowitz, and JH Antin |
| |
JCO Sep 1 1998: 2897–2903.
[Abstract]
[PDF]
|
 |
| The evolution of cancer care for children and adults |
| JV Simone and J Lyons |
|
JCO Sep 1 1998: 2904–2905.
[PDF]
|
|
|
Prophylactic isolated limb perfusion for localized, high-risk limb melanoma: results of a multicenter randomized phase III trial. European Organization for Research and Treatment of Cancer Malignant Melanoma Cooperative Group Protocol 18832, the World Health Organization Melanoma Program Trial 15, and the North American Perfusion Group Southwest Oncology Group-8593 |
| |
HS Koops, M Vaglini, S Suciu, BB Kroon, JF Thompson, J Gohl, AM Eggermont, F Di Filippo, ET Krementz, D Ruiter, and FJ Lejeune |
| |
JCO Sep 1 1998: 2906–2912.
[Abstract]
[PDF]
|
|
|
Correlation of specific immune responses with survival in melanoma patients with distant metastases receiving polyvalent melanoma cell vaccine |
| |
EC Hsueh, RK Gupta, K Qi, and DL Morton |
| |
JCO Sep 1 1998: 2913–2920.
[Abstract]
[PDF]
|
|
|
Results of interleukin-2-based treatment in advanced melanoma: a case record-based analysis of 631 patients |
| |
U Keilholz, C Conradt, SS Legha, D Khayat, C Scheibenbogen, N Thatcher, SH Goey, M Gore, T Dorval, B Hancock, CJ Punt, R Dummer, MF Avril, EB Brocker, A Benhammouda, AM Eggermont, and M Pritsch |
| |
JCO Sep 1 1998: 2921–2929.
[Abstract]
[PDF]
|
|
|
Granulocyte-macrophage colony-stimulating factor in patients with neutropenic fever is potent after low-risk but not after high-risk neutropenic chemotherapy regimens: results of a randomized phase III trial |
| |
A Ravaud, C Chevreau, L Cany, P Houyau, N Dohollou, H Roche, P Soubeyran, F Bonichon, J Mihura, H Eghbali, I Tabah, and BN Bui |
| |
JCO Sep 1 1998: 2930–2936.
[Abstract]
[PDF]
|
|
|
Double-blind, dose-finding study of four intravenous doses of dexamethasone in the prevention of cisplatin-induced acute emesis. Italian Group for Antiemetic Research |
| |
|
| |
JCO Sep 1 1998: 2937–2942.
[Abstract]
[PDF]
|
|
|
Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. Tomudex Colorectal Cancer Study Group |
| |
G Cocconi, D Cunningham, E Van Cutsem, E Francois, B Gustavsson, G van Hazel, D Kerr, K Possinger, and SM Hietschold |
| |
JCO Sep 1 1998: 2943–2952.
[Abstract]
[PDF]
|
|
|
Phase II trial of nitrogen mustard, vincristine, and procarbazine in patients with recurrent glioma: North Central Cancer Treatment Group results |
| |
E Galanis, JC Buckner, PA Burch, PL Schaefer, RP Dinapoli, PJ Novotny, BW Scheithauer, KM Rowland, AM Vukov, JA Mailliard, and RF Morton |
| |
JCO Sep 1 1998: 2953–2958.
[Abstract]
[PDF]
|
|
|
Phase I and pharmacologic study of estramustine phosphate and short infusions of paclitaxel in women with solid tumors |
| |
AA Garcia, S Keren-Rosenberg, D Parimoo, M Rogers, S Jeffers, R Koda, and FM Muggia |
| |
JCO Sep 1 1998: 2959–2963.
[Abstract]
[PDF]
|
|
|
Phase I and pharmacokinetic study of paclitaxel in combination with biricodar, a novel agent that reverses multidrug resistance conferred by overexpression of both MDR1 and MRP |
| |
EK Rowinsky, L Smith, YM Wang, P Chaturvedi, M Villalona, E Campbell, C Aylesworth, SG Eckhardt, L Hammond, M Kraynak, R Drengler, J Stephenson, Jr, MW Harding, and DD Von Hoff |
| |
JCO Sep 1 1998: 2964–2976.
[Abstract]
[PDF]
|
|
|
Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer |
| |
M Mackean, A Planting, C Twelves, J Schellens, D Allman, B Osterwalder, B Reigner, T Griffin, S Kaye, and J Verweij |
| |
JCO Sep 1 1998: 2977–2985.
[Abstract]
[PDF]
|
|
|
Phase I trial of continuous infusion flavopiridol, a novel cyclin- dependent kinase inhibitor, in patients with refractory neoplasms |
| |
AM Senderowicz, D Headlee, SF Stinson, RM Lush, N Kalil, L Villalba, K Hill, SM Steinberg, WD Figg, A Tompkins, SG Arbuck, and EA Sausville |
| |
JCO Sep 1 1998: 2986–2999.
[Abstract]
[PDF]
|
|
|
Phase II trial of chemotherapy alone for primary CNS and intraocular lymphoma |
| |
V Sandor, V Stark-Vancs, D Pearson, R Nussenblat, SM Whitcup, P Brouwers, N Patronas, J Heiss, E Jaffe, M deSmet, D Kohler, R Simon, and R Wittes |
| |
JCO Sep 1 1998: 3000–3006.
[Abstract]
[PDF]
|
|
|
Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine via the Group C protocol mechanism of the National Cancer Institute: a report of 979 patients |
| |
BD Cheson, JM Sorensen, DA Vena, MJ Montello, JA Barrett, E Damasio, M Tallman, L Annino, J Connors, B Coiffier, and F Lauria |
| |
JCO Sep 1 1998: 3007–3015.
[Abstract]
[PDF]
|
|
|
High risk of leukemia after short-term dose-intensive chemotherapy in young patients with solid tumors |
| |
BH Kushner, G Heller, NK Cheung, N Wollner, K Kramer, D Bajorin, T Polyak, and PA Meyers |
| |
JCO Sep 1 1998: 3016–3020.
[Abstract]
[PDF]
|
|
|
Combination chemotherapy using vinblastine and methotrexate for the treatment of progressive desmoid tumor in children |
| |
SX Skapek, BJ Hawk, FA Hoffer, GV Dahl, L Granowetter, MC Gebhardt, WS Ferguson, and HE Grier |
| |
JCO Sep 1 1998: 3021–3027.
[Abstract]
[PDF]
|
|
|
Clinical, pathologic, and molecular spectrum of tumors associated with t(11;22)(p13;q12): desmoplastic small round-cell tumor and its variants |
| |
WL Gerald, M Ladanyi, E de Alava, M Cuatrecasas, BH Kushner, MP LaQuaglia, and J Rosai |
| |
JCO Sep 1 1998: 3028–3036.
[Abstract]
[PDF]
|
|
|
Phase I study of temozolomide in children and adolescents with recurrent solid tumors: a report from the Children's Cancer Group |
| |
HS Nicholson, M Krailo, MM Ames, NL Seibel, JM Reid, W Liu-Mares, LG Vezina, AG Ettinger, and GH Reaman |
| |
JCO Sep 1 1998: 3037–3043.
[Abstract]
[PDF]
|
|
|
Ewing's tumors with primary lung metastases: survival analysis of 114 (European Intergroup) Cooperative Ewing's Sarcoma Studies patients |
| |
M Paulussen, S Ahrens, AW Craft, J Dunst, B Frohlich, S Jabar, C Rube, W Winkelmann, S Wissing, A Zoubek, and H Jurgens |
| |
JCO Sep 1 1998: 3044–3052.
[Abstract]
[PDF]
|
|
|
Anti-G(D2) antibody treatment of minimal residual stage 4 neuroblastoma diagnosed at more than 1 year of age |
| |
NK Cheung, BH Kushner, IY Cheung, K Kramer, A Canete, W Gerald, MA Bonilla, R Finn, SJ Yeh, and SM Larson |
| |
JCO Sep 1 1998: 3053–3060.
[Abstract]
[PDF]
|
|
|
Detection of K-ras point mutations in sputum from patients with adenocarcinoma of the lung by point-EXACCT |
| |
VA Somers, AM Pietersen, PH Theunissen, and FB Thunnissen |
| |
JCO Sep 1 1998: 3061–3068.
[Abstract]
[PDF]
|
|
|
Clinical relevance of cyclin D1 protein overexpression in laryngeal squamous cell carcinoma |
| |
L Pignataro, G Pruneri, N Carboni, P Capaccio, BM Cesana, A Neri, and R Buffa |
| |
JCO Sep 1 1998: 3069–3077.
[Abstract]
[PDF]
|
|
|
Southwest Oncology Group phase II trial of concurrent carboplatin, etoposide, and radiation for poor-risk stage III non-small-cell lung cancer |
| |
DH Lau, JJ Crowley, DR Gandara, MB Hazuka, KS Albain, B Leigh, WS Fletcher, KS Lanier, WL Keiser, and RB Livingston |
| |
JCO Sep 1 1998: 3078–3081.
[Abstract]
[PDF]
|
|
|
Patient-reported short-term and long-term physical and psychologic symptoms: results of the continuous hyperfractionated accelerated [correction of acclerated] radiotherapy (CHART) randomized trial in non- small-cell lung cancer. CHART Steering Committee |
| |
AJ Bailey, MK Parmar, and RJ Stephens |
| |
JCO Sep 1 1998: 3082–3093.
[Abstract]
[PDF]
|
|
|
Calculated prostate cancer volume greater than 4.0 cm3 identifies patients with localized prostate cancer who have a poor prognosis following radical prostatectomy or external-beam radiation therapy |
| |
AV D'Amico, R Whittington, SB Malkowicz, D Schultz, I Kaplan, CJ Beard, JE Tomaszewski, AA Renshaw, KR Loughlin, JP Richie, and A Wein |
| |
JCO Sep 1 1998: 3094–3100.
[Abstract]
[PDF]
|
|
|
Relation between literacy, race, and stage of presentation among low- income patients with prostate cancer |
| |
CL Bennett, MR Ferreira, TC Davis, J Kaplan, M Weinberger, T Kuzel, MA Seday, and O Sartor |
| |
JCO Sep 1 1998: 3101–3104.
[Abstract]
[PDF]
|
|
|
Risk-based recommendations for mammographic screening for women in their forties |
| |
M Gail and B Rimer |
| |
JCO Sep 1 1998: 3105–3114.
[Abstract]
[PDF]
|
|
|
Low biologic aggressiveness in breast cancer in women using hormone replacement therapy |
| |
K Holli, J Isola, and J Cuzick |
| |
JCO Sep 1 1998: 3115–3120.
[Abstract]
[PDF]
|
|
|
Vascular endothelial growth factor is of high prognostic value in node- negative breast carcinoma |
| |
B Linderholm, B Tavelin, K Grankvist, and R Henriksson |
| |
JCO Sep 1 1998: 3121–3128.
[Abstract]
[PDF]
|
|
|
Markers of tumor angiogenesis and proteolysis independently define high- and low-risk subsets of node-negative breast cancer patients |
| |
U Eppenberger, W Kueng, JM Schlaeppi, JL Roesel, C Benz, H Mueller, A Matter, M Zuber, K Luescher, M Litschgi, M Schmitt, JA Foekens, and S Eppenberger- Castori |
| |
JCO Sep 1 1998: 3129–3136.
[Abstract]
[PDF]
|
|
|
A single scale for comparing dose-intensity of all chemotherapy regimens in breast cancer: summation dose-intensity |
| |
W Hryniuk, E Frei, 3rd, and FA Wright |
| |
JCO Sep 1 1998: 3137–3147.
[Abstract]
[PDF]
|
|
|
Prevalence and predictors of sexual dysfunction in long-term survivors of marrow transplantation |
| |
KL Syrjala, SL Roth-Roemer, JR Abrams, JM Scanlan, MK Chapko, S Visser, and JE Sanders |
| |
JCO Sep 1 1998: 3148–3157.
[Abstract]
[PDF]
|
|
|
Tumor-suppressor p53: implications for tumor development and prognosis |
| |
DG Kirsch and MB Kastan |
| |
JCO Sep 1 1998: 3158–3168.
[Abstract]
[PDF]
|
|
|
Recommended guidelines for the treatment of chemotherapy-induced diarrhea |
| |
S Wadler, AB Benson, 3rd, C Engelking, R Catalano, M Field, SM Kornblau, E Mitchell, J Rubin, P Trotta, and E Vokes |
| |
JCO Sep 1 1998: 3169–3178.
[Abstract]
[PDF]
|
|
|
Design and interpretation of clinical trials that evaluate agents that may offer protection from the toxic effects of cancer chemotherapy |
| |
KA Phillips and IF Tannock |
| |
JCO Sep 1 1998: 3179–3190.
[Abstract]
[PDF]
|
|
| The state of the society: a year of continued growth |
| RJ Mayer |
|
JCO Sep 1 1998: 3192–3198.
[PDF]
|
|
| Complications of acute leukemia. Case one: congenital acute myelogenous leukemia with cutaneous involvement |
| HA Frangoul and K Patterson |
|
JCO Sep 1 1998: 3199–3200.
[PDF]
|
|
| Complications of acute leukemia. Case two: epidural chloroma of the lower spinal canal |
| GM Proulx and P McCarthy |
|
JCO Sep 1 1998: 3201–3202.
[PDF]
|
|
| Patient-physician relation and unproven therapies |
| D Tassinari, F Desiderio, A Ravaioli, and S Sartori |
|
JCO Sep 1 1998: 3203.
[PDF]
|
|
| Relevant clinical end points in biphosphonate trials |
| JR Berenson, P Major, and G Hortabagyi |
|
JCO Sep 1 1998: 3204–3205.
[PDF]
|
|
| Late pulmonary toxicity of bleomycin |
| W Willenbacher, A Mumm, and HH Bartsch |
|
JCO Sep 1 1998: 3205a.
[PDF]
|
|
| Adjuvant interferon for stage II melanoma |
| FG Haluska |
|
JCO Sep 1 1998: 3205b–3206.
[PDF]
|
|
| BRCA mutations and survival in breast cancer |
| WD Foulkes, N Wong, JS Brunet, and SA Narod |
|
JCO Sep 1 1998: 3206–3208.
[PDF]
|
|
| Is ascitic fluid interleukin-12 an independent prognostic factor in ovarian cancer? The necessity of correction milligram P values for multiple comparisons |
| AP Kudelka, R Lenzi, EN Atkinson, LB Levy, and RS Freedman |
|
JCO Sep 1 1998: 3208–3209.
[PDF]
|
|
| Fludarabine and hemolytic anemia in chronic lymphocytic leukemia |
| TJ Hamblin, JA Orchard, H Myint, and DG Oscier |
|
JCO Sep 1 1998: 3209–3210.
[PDF]
|
|
| Cognition in survivors of high-grade glioma |
| JG Cairncross |
|
JCO Sep 1 1998: 3210–3211.
[PDF]
|
|
